Frontiers Summer 2014
This is an especially exciting period at both The Ohio State University and the OSUCCC – James.
On July 1, Michael V. Drake, MD, became Ohio State’s 15th president.
Dr. Drake is a tremendously accomplished and dynamic individual who came to Ohio State after serving nine years as chancellor at the University of California, Irvine. There, he also served as a Distinguished Professor of Ophthalmology and of Education and oversaw a significant expansion and development of the university, including new programs in public health, pharmaceutical sciences and nursing science.
We welcome Dr. Drake – the first medical doctor to serve as president of Ohio State – as we move forward with expansion of our cancer program.
That expansion will make Ohio State history with the opening of the new James Cancer Hospital and Solove Research Institute in December. Te weekend of Dec. 13-14, we will transfer patients from the original James – the site of cutting-edge, compassionate care since 1990 – to the new James, which will be fully and officially open Dec. 15.
The new hospital features the nation’s first fully integrated cancer emergency department, subspecialty care by floor, translational research labs on all inpatient floors and much more.
Finally, I want to mention John Byrd, MD, and his team. The Clinical Research Forum selected them to receive one of its Top 10 Clinical Research Achievement Awards in the United States for 2014 for studies of the drug ibrutinib, a targeted agent for chronic lymphocytic leukemia (CLL).
John’s team identified ibrutinib’s mechanism of action, and John led the first early-phase trial of ibrutinib in CLL. The outcome of that trial prompted the U.S. Food and Drug Administration to designate the drug a Breakthrough Therapy. Other work by John and his lab has led to phase III trials that could make oral ibrutinib an initial therapy for CLL.
John is one of nearly 300 researchers and 200 cancer subspecialists at the OSUCCC – James working to help patients and achieve our vision of a cancer-free world.